Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Market outlook

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction, which is characterized by muscle weakness and fatigue. Acetylcholine inhibitors (e.g., pyridostigmine) and short- and long-term immunosuppressants, such as prednisone, mycophenolate mofetil, and azathioprine, are the most prescribed agents to manage MG symptoms. However, the MG pipeline is starting to bring novel therapies with unique mechanisms of action to the market, highlighted by the FDA approval of eculizumab (Alexion / AstraZeneca’s Soliris) and efgartigimod alfa (Argenx’s Vyvgart) in 2017 and December 2021, respectively. As the MG current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in MG to help new players better understand current treatment practices in MG and to define the market niche for their emerging products.For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed myasthenia gravis (MG) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MG patients?
  • How has Soliris been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of MG patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of MG patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Alexion Pharma

Key drugs: Pyridostigmine, prednisone, azathioprine, mycophenolate mofetil, Soliris, Rituxan, intravenous immunoglobulin

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Myasthenia Gravis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Myasthenia Gravis US February 2022
    • Treatment Algorithms CDA Myasthenia Gravis 2022 Dashboard

Login to access report

launch Related Market Assessment Reports